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Background: Individuals with chronic diseases may have difficulty optimizing their health and getting the care
they need due to a combination of patient, provider, and health system level barriers. Patient navigator programs,
in which trained personnel assess and assist patients in overcoming barriers to care, may improve care and
outcomes for patients with chronic disease by providing an alternative approach to conventional information and
support resources.
Methods: This systematic review will evaluate the evidence for patient navigator programs, compared to usual
care, in patients with chronic disease. We will include RCTs, cluster RCTs, and quasi-randomized RCTs that study the
effects of patient navigator programs on clinical outcomes, patient experience, and markers of adherence to care.
Studies will be identified by searching MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL),
CINAHL, PsycINFO, Social Work Abstracts, and the references of included studies. Two authors will screen titles
and abstracts independently. Full texts will be reviewed for relevance and data extraction will be done independently
by two authors. Studies will be included if they assess patients of any age with one or more chronic diseases. Outcomes
will be categorized into groups characterized by their proximity to mechanism of action of the intervention: patient-level
outcomes, intermediate outcomes, and process outcomes. Descriptive data about the elements of the patient navigator
intervention will also be collected for potential subgroup analyses. Risk of bias will be assessed using the Effective
Practice and Organisation of Care Group (EPOC) risk of bias tool. Data will be analyzed using random effects
meta-analysis (relative risk for dichotomous data and mean difference for continuous data), if appropriate.
Discussion: A comprehensive review of patient navigator programs, including a summary of the elements of
programs that are associated with a successful intervention, does not yet exist. This systematic review will
synthesize the evidence of the effect of patient navigator interventions on clinical and patient-oriented outcomes in
populations across a comprehensive set of chronic diseases.
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Chronic diseases are a significant burden to patients and the
health care system. They include both physical and mental
illnesses and affect at least one third of all Canadians; of
Canadian adults with a chronic disease, over a third have
two or more conditions [1]. People with chronic conditions
have increased morbidity and consume substantially more
health care resources than those without [1,2]. Adherence to
guidelines and the achievement of treatment targets is asso-
ciated with better outcomes and a lower rate of resource
utilization for patients with chronic diseases [3-5]. For ex-
ample, tight control of blood pressure in patients with type
2 diabetes leads to a significant increase in time to develop-
ment of complications, without significantly increasing the
total cost of care [3]. Despite guidelines, many people with
chronic diseases do not receive recommended care [6-9].
Individuals with chronic diseases may have difficulty
achieving care goals due to a combination of patient,
provider, and system level barriers [10]. System level bar-
riers include the inherent complexity of the health care
system and poor access to primary or specialty care. At
the provider level, barriers may include the lack of sup-
port systems to implement recommended care. Patient
level barriers may include lack of awareness of publicly
funded programs including community-based resources,
financial constraints, competing priorities (e.g., family
and work), and personal circumstances that make fol-
lowing complex care plans particularly challenging. Survey
data have demonstrated that barriers for Canadians with a
greater number of chronic conditions include being older,
less educated, less well off financially, and living in a rural
area [2].
Patient navigator programs may help patients with
chronic disease achieve their care goals by providing a
tailored approach to addressing their specific needs.
Patient navigators are trained personnel who aid pa-
tients in overcoming barriers to care. The primary role
of the navigator is not clinically oriented, and navigators
may be nurses, social workers, or lay health workers. They
differ from clinical case managers in that they provide no
clinical care.
Patient navigator programs were originally established
to reduce gaps in cancer care among marginalized popu-
lations [11] and are increasingly in use across the United
States and Canada [12]. All existing patient navigator
programs have the underlying goal of helping patients to
overcome modifiable barriers to care to achieve optimal
outcomes [13-15]. Depending on the targeted barriers,
specific tasks may include one or more of disease educa-
tion [16,17], health system education [16,18,19], assistance
with insurance coverage [20], aid in care coordination [16],
and referral to community resources [17], among others.
Reviews by Wells [15] and Paskett [21] of patient naviga-
tors in cancer care found that patient navigator programsimproved screening adherence rates and suggested that
they improved adherence to diagnostic services and im-
proved cancer stage at diagnosis. Other randomized con-
trolled trials indicate that patient navigators improve the
rate of enrolment in a community cardiac rehabilitation
program [19] and in the completion of steps in the kidney
transplant process [22]. However, there is wide variation in
the design and implementation of patient navigator pro-
grams, and no systematic review to date has summarized
the characteristics of successful programs. The purposes of
this study are:
1. To assess the effects of patient navigator services,
compared with usual care, on the achievement of
recommended processes of care and on patient-oriented
outcomes in patients with chronic diseases.
2. To explore whether attributes of patient navigator








Studies will be included when the subjects were patients
who have or are being screened for one or more chronic
conditions including those of acquired infectious eti-
ology and inherited genetic predisposition. The chronic
conditions included in Statistics Canada community sur-
veys [23] that are expected to last 6 months or more will
be considered, including asthma; arthritis; hypertension;
migraine; COPD/emphysema; diabetes; heart disease;
cancer; intestinal/stomach ulcers; stroke; urinary incon-
tinence; inflammatory bowel disorder; dementia; mood
disorders; anxiety disorders, with the addition of chronic
kidney disease, which includes transplant recipients and
patients on dialysis; and HIV/AIDS. Participants of all
ages will be included and the intervention may be directed
to either the patient or their immediate caregivers.
Exclusion criteria
Studies with patients without one or more of the chronic
diseases listed above will not be included.
Types of interventions
Studies that examine the effects of a patient navigator
intervention will be considered. For the purposes of this
review, a patient navigator is a person with or without a
health care-related background that engages with pa-
tients on an individual basis to determine barriers to
accessing care or following recommended guidelines,
Table 1 Description of data extracted from each included
study
Data Description
Type of study RCT, cluster RCT, and quasi-randomized
RCT




Mean age, percentage female, illness under
study
Details of patient navigator
services
Professional background of navigators,
scope of services, location and frequency
of intervention
Control condition and use
of co-interventions
Outcomes assessed Primary and secondary outcomes as
defined by authors
Study duration Recruitment period, intervention
duration, and total study duration
Results Changes in outcomes
Funding source Industry vs. other
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cumstances in order to increase access to components
of the health care system and to enhance their chronic
disease care. Navigators do not provide clinical advice,
but rather focus on helping patients to access, under-
stand, or better utilize available health care resources.
Navigators may go by a different name, e.g., promotoras,
lay health worker, care guide, and so on, and any of
these will be included if they meet the above definition.
The navigator role must be formalized, as opposed to
casual, untrained peer, family, or friend support. Peer
support persons or former patients who have been for-
mally trained in a navigator role will be included. The
independent initiation of medical treatments or investi-
gations will be considered to be out of scope of patient
navigator programs. Professionals carrying out such tasks
may be better defined as integrated or clinical case
managers [24].
The comparator group will be no intervention, stand-
ard or usual care, or interventions of lower intensity,
e.g., educational pamphlet. If more than one compara-
tor group is used, we will choose the arm that most
closely resembles usual or standard care.
Outcome measures
Including a diverse group of chronic diseases will lead to
predictably heterogeneous outcome measures. We have
purposely kept our outcome list broad in order to include
all relevant outcomes that may be reported. To facilitate
our goal of summarizing the data, we will categorize out-
comes into groups characterized by their proximity to
mechanism of action of the intervention: patient-level
outcomes, intermediate outcomes, and process outcomes.
Patient-level measures of interest include mortality,
health-related quality of life, and complications of sub-
optimal disease management such as cardiovascular
events. Intermediate measures include disease-specific
clinical measures such as glycemic control. Process
measures include the expected immediate targets of the
intervention such as increased access to appropriate ser-
vice providers as well as adherence to recommended
clinical actions including guideline-concordant use of
medications or investigations. Finally, we will assess
measures of patient experience and/or patient satisfac-
tion with the navigator intervention.
Search method
Databases that will be searched are MEDLINE, Embase, the
Cochrane Central Register of Controlled Trials (CENTRAL),
CINAHL, PsycINFO, and Social Work Abstracts. There will
be no date restrictions. The MEDLINE search strategy was
peer reviewed via PRESS (Appendix).
The search of online databases will include all lan-
guages of publication and will be tailored to specificdatabases by an expert librarian. In addition, the refer-
ence lists of included articles and systematic and narra-
tive reviews identified in the electronic search will be
reviewed.
Investigators of included published protocols will be
contacted for information about other ongoing or un-
published studies.
Data collection and analysis
Two reviewers will screen titles and abstracts independ-
ently, and all studies potentially eligible for inclusion will
be retained for full-text review. Two reviewers will then
independently screen full-text articles for inclusion or
exclusion. Disagreements will be resolved by discussion
or with a third reviewer as required.
Data extraction will be done independently by two re-
viewers using standard data extraction forms; details are
presented in Table 1. Original authors will be contacted
in writing for requests of any missing data.
Risk of bias assessment
The risk of bias criteria suggested by the Cochrane
Effective Practice and Organisation of Care Group
(EPOC) will be used to assess the risk of bias in each
included study [25]. The tool includes an assessment
of bias in nine domains: sequence generation, alloca-
tion concealment, baseline outcome measurements
between groups, similarity of baseline characteristics,
completeness of data, blinding of outcome assessment,
protection against contamination, selective outcome report-
ing, and other. The selective recruitment of cluster partici-
pants will be included as an additional domain for cluster
RCTs. Two authors will independently assess risk of bias in
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clear. Disagreements will be resolved by discussion or with
a third reviewer as needed.
Data synthesis
For the primary analysis, all studies with outcomes in
the above described categories will be grouped together
and results will be summarized by outcome category. A
goal of this study is to provide a quantitative assess-
ment of the effects of patient navigator services over a
predictably heterogeneous group of chronic diseases and
outcomes. Therefore, due to anticipated variability in pop-
ulations and interventions, we will use a stepped approach
to data synthesis. If three or more studies report the same
outcome within a category, and there are no apparent unit
of analysis errors (or intraclass correlation coefficient (ICC)
data are available), traditional random effects meta-analysis
will be conducted, using standard methods to account for
cluster trials as relevant [26,27]. We will report relative risk
for dichotomous outcomes and standard mean difference
for continuous outcomes. Heterogeneity will be assessed
by visual inspection of forest plots, the chi2 test, and
quantified by the I2 statistic. If significant clinical,
methodological, or statistical (I2 value of 50% or more)
heterogeneity exists, data will not be pooled.
For outcomes that do not meet these criteria but for
which data are dichotomous and where there are three
or more studies within a category, we will use a previ-
ously described quantitative strategy for reporting me-
dian effect sizes [28]. First, for studies with multiple
dichotomous outcomes that fall within a category of
interest, for example adherence to recommended clinical
action, the median effect size - the difference in propor-
tions between the intervention and control - will be cal-
culated for all reported outcomes in that category within
that study. The median effect size will represent a single
outcome for each study. These data will then be ana-
lyzed together and a median effect size and interquartile
range across studies will be reported. This approach of
using a ‘median of medians’ avoids the use of numerous
assumptions to estimate the ICC and avoids skewing by
outlying studies. For all other outcomes and circum-
stances, we will use a narrative approach to data synthesis.
We will pursue exploratory analyses to investigate for
differences in outcomes based on the groupings below
by stratifying analyses if adequate studies exist in each
category. Where median effect sizes were estimated, we
will explore potential associations between subgroup
characteristics and effect size using a nonparametric
Mann-Whitney rank-sum test.
1. Type of disease - cancer, mental health, chronic
cardiovascular related diseases (i.e., hypertension,
diabetes, cardiovascular disease), other diseases2. Intensity/type of navigator services - lay navigators,
professional navigator, telephone-based, in-person
services, embedded within care team, external to
care team
3. Patient demographic - adult, pediatric, elderly, >50%
with low socioeconomic status, >50% minority
patients.
A sensitivity analysis will be done in which we exclude
studies at high risk of bias in any of the nine domains
listed above. Further, we will perform an additional sen-
sitivity analysis excluding studies focused on disease
screening, due to the potential for substantial differences
in patient populations and the behavior changes targeted
by the intervention.
Discussion
A comprehensive review of patient navigator programs,
including a summary of the elements of programs that
are associated with a successful intervention, does not
yet exist in the literature. The reviews by Wells et al.
and Paskett et al. found a total of 33 studies on patient
navigator programs in cancer that reported on patient
outcomes [15,21]. There was wide variation in interven-
tion design, study design, and study quality. In addition,
these reviews were restricted to cancer care and did not
include a meta-analytic component. The purpose of the
present study is to comprehensively and systematically
synthesize the evidence of effect of patient navigator in-
terventions on clinical and patient-oriented outcomes in
populations across chronic diseases. A thorough and
high-quality systematic review of patient navigator pro-
grams is needed to 1) translate the current evidence into
effective navigator programs, 2) determine key outcomes
for future intervention studies, and 3) identify areas for
further study. This review will provide important infor-
mation to those who are contemplating, implementing,
or testing a similar intervention.
Appendix: Literature Search
Ovid MEDLINE® search strategy with no date restrictions.
1. "Continuity of Patient Care"/
2. patient navigation/ or exp patient-centered care/ or
case management/
3. ((care or coach* or service* or system*) adj5 (coordinat*
or facilitat* or navigat* or transition*)).tw.
4. ((patient* or system* or service*) adj5 (coach* or
facilitat* or navigat*)).tw.
5. (guided adj2 care).tw.
6. (case manager* or case management or navigator or
navigators).tw.
7. post-discharge support*.tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. Chronic Disease/
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11. exp Alzheimer Disease/
12. exp Anxiety Disorders/
13. exp Arthritis/
14. exp Asthma/
15. exp Intestinal Diseases/ or exp Irritable Bowel
Syndrome/ or exp Colonic Diseases, Functional/or exp
Gastrointestinal Diseases/or exp Inflammatory Bowel
Diseases/ or exp Crohn Disease/or exp Colitis, Ulcerative/
16. exp Pulmonary Disease, Chronic Obstructive/
17. exp Cerebrovascular Disorders/
18. exp Renal Insufficiency, Chronic/
19. exp Dementia/
20. Depression/
21. exp Depressive Disorder/
22. exp Diabetes Mellitus/
23. exp Emphysema/
24. exp Myocardial Infarction/
25. exp Heart Diseases/
26. exp HIV/ or exp HIV Infections/
27. exp Hypertension/
28. exp Neoplasms/
29. exp Migraine Disorders/
30. exp Mood Disorders/
31. exp Obsessive-Compulsive Disorder/
32. exp Panic Disorder/
33. exp Phobic Disorders/
34. exp Stroke/
35. Ulcer/ or exp peptic ulcer/
36. exp Urinary Incontinence/
37. exp Renal Dialysis/
38. exp Kidney Transplantation/
39. (AIDS or acquired immunodeficiency disorder*
or affective disorder* or alzheimer* or agina* or anx-
iety* or arthritis or asthma or atrial fibrillation or
arrhythmia* or bipolar or bladder incontin* or bowel
disorder* or brain infarc* or cancer* or carcinoma* or
cardiomyopath* or COPD or COAD or cerebral haem-
orrhage or cerebral hemorrhage or cerebrovascular
disease* or chronic airflow obstruction* or chronic
condition* or chronic disease* or chronic illness* or
chronic kidney disease* or chronic obstructive airway*
disease* or chronic obstructive pulmonary disease* or
cognitive impair* or combat disorder* or (coronary
adj2 disease*) or crohns or dementia or depressi* or
diabetes or diabetic* or dialysis or emphysema or
gastrointestinal disease* or haemodialysis or heart ar-
rest or heart attack* or heart disease* or heart failure
or heart infarction* or hemodialysis or HIV* or human
immunodeficiency virus* or human immuno-deficiency
virus* or hypertens* or inflammatory bowel disease* or
IBD or irritable bowel* or isch?emia* or insulin-depend*
or intracranial h?emorrhage* or intra-cranial h?emor-
rhage* or kidney transplant* or longterm condition* orlong-term condition* or longterm disease* or long-term
disease* or longterm illness* or long-term illness* or
manic disorder* or migraine* or mood disorder* or myo-
cardial infarc* or neoplasia* or neoplastic or neoplasm* or
neurosis or neuroses or neurotic or OCD or obsessive
compulsive disorder* or obstructive lung disease* or ob-
structive pulmonary disease* or PTSD or panic attack* or
panic disorder* or phobia* or post-trauma or posttrauma
or renal dialysis or stroke or tumor* or tumour* or ulcer
or ulcers or ulcerative colitis or urinary incontinence or
urination disorder* or ventricular fibrillation).tw.
40. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or
27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
or 37 or 38 or 39
41. 8 and 40
42. (randomized controlled trial or controlled clinical
trial).pt.
43. drug therapy.sh.
44. (groups or placebo or randomized or randomly
or trial).tw.
45. 42 or 43 or 44
46. 41 and 45
47. (animals not humans).sh.
48. 46 not 47
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